Dynamic ctDNA Monitoring Guides Early Treatment Intensification in Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemotherapy
Dynamic ctDNA monitoring identifies LARC patients at high risk for NCT failure as early as two cycles into treatment, which can form the basis for an adaptive trial design and eventual personalization of therapy selection.
Authors
- Zhuang Lu (ORCID: https://orcid.org/0000-0002-1826-363X)
- Rui Fan (ORCID: https://orcid.org/0009-0006-0609-5081)
- H R Chen
- Wenjian Meng (ORCID: https://orcid.org/0000-0002-3247-9007)
- Min Qiu (ORCID: https://orcid.org/0000-0002-7373-2355)
- Yiqian Liu
- Dan Jiang (ORCID: https://orcid.org/0000-0002-9254-6048)
- Tian Yang (ORCID: https://orcid.org/0009-0006-2832-5351)
- Xiafei Gu
- Q. Li
- Qingbin Wu
- Yazhou He (ORCID: https://orcid.org/0000-0003-2358-0143)
- Feifei Li
- Mingtian Wei
- Yu Shen
- Xiangbing Deng
- Ziqiang Wang
Institutions
- Sichuan University (CN)
- West China Medical Center of Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
- Chengdu University (CN)
- Genecast (China) (CN)
- Imperial College London (GB)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3774
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00